# Pomalidomide, Dexamethasone and Rituximab in Waldenstrom's Macroglobulinemia

> **NCT01078974** · PHASE1 · TERMINATED · sponsor: **Steven P. Treon, MD, PhD** · enrollment: 7 (actual)

## Conditions studied

- Waldenstrom's Macroglobulinemia

## Interventions

- **DRUG:** pomalidomide
- **DRUG:** dexamethasone
- **DRUG:** rituximab

## Key facts

- **NCT ID:** NCT01078974
- **Lead sponsor:** Steven P. Treon, MD, PhD
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-05
- **Primary completion:** 2015-09
- **Final completion:** 2016-03
- **Target enrollment:** 7 (ACTUAL)
- **Why stopped:** Safety concerns (IgM Flare)
- **Last updated:** 2016-07-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01078974

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01078974, "Pomalidomide, Dexamethasone and Rituximab in Waldenstrom's Macroglobulinemia". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01078974. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*